Electroretinography

From Wikipedia, the free encyclopedia
  (Redirected from Electroretinogram)
Jump to: navigation, search
Electroretinography
Intervention
Maximal Response ERG.png
Maximal response ERG waveform from a dark adapted eye.
ICD-9-CM 95.21
MeSH D004596
An electroretinogram (ERG) test performed in 2014.
A historical photo of a patient undergoing an electroretinogram.

Electroretinography measures the electrical responses of various cell types in the retina, including the photoreceptors (rods and cones), inner retinal cells (bipolar and amacrine cells), and the ganglion cells. Electrodes are usually placed on the cornea and the skin near the eye, although it is possible to record the ERG from skin electrodes. During a recording, the patient's eyes are exposed to standardized stimuli and the resulting signal is displayed showing the time course of the signal's amplitude (voltage). Signals are very small, and typically are measured in microvolts or nanovolts. The ERG is composed of electrical potentials contributed by different cell types within the retina, and the stimulus conditions (flash or pattern stimulus, whether a background light is present, and the colors of the stimulus and background) can elicit stronger response from certain components.

If a dim flash ERG is performed on a dark-adapted eye, the response is primarily from the rod system. Flash ERGs performed on a light adapted eye will reflect the activity of the cone system. Sufficiently bright flashes will elicit ERGs containing an a-wave (initial negative deflection) followed by a b-wave (positive deflection). The leading edge of the a-wave is produced by the photoreceptors, while the remainder of the wave is produced by a mixture of cells including photoreceptors, bipolar, amacrine, and Muller cells or Muller glia.[1] The pattern ERG, evoked by an alternating checkerboard stimulus, primarily reflects activity of retinal ganglion cells.

Clinically used mainly by ophthalmologists and optometrists, the electroretinogram (ERG) is used for the diagnosis of various retinal diseases.[2]

Inherited retinal degenerations in which the ERG can be useful include:

Other ocular disorders in which the standard ERG provides useful information include:

  • Diabetic retinopathy
  • Other ischemic retinopathies including central retinal vein occlusion (CRVO), branch vein occlusion (BVO), and sickle cell retinopathy
  • Toxic retinopathies, including those caused by Plaquenil and Vigabatrin. The ERG is also used to monitor retinal toxicity in many drug trials.
  • Autoimmune retinopathies such as Cancer Associated Retinopathy (CAR), Melanoma Associated Retinopathy (MAR), and Acute Zonal Occult Outer Retinopathy (AZOOR)
  • Retinal detachment
  • Assessment of retinal function after trauma, especially in vitreous hemorrhage, dense cataracts, and other conditions where the fundus cannot be visualized.

The ERG is also used extensively in eye research, as it provides information about the function of the retina that is not otherwise available.

Other ERG tests, such as the Photopic Negative Response (PhNR) and pattern ERG (PERG) may be useful in assessing retinal ganglion cell function in diseases like glaucoma.

The multifocal ERG is used to record separate responses for different retinal locations.

The international body concerned with the clinical use and standardization of the ERG, EOG, and VEP is the International Society for the Clinical Electrophysiology of Vision (ISCEV) [3]

In addition to its clinical diagnostic purpose, the ERG can be used during the course of drug development and in clinical trails for testing ocular safety and efficacy of new or existing drugs and treatment modalities [4]

References[edit]

  1. ^ Webvision at University of Utah
  2. ^ Electroretinography, U.S. National Library of Medicine, 11 April 2005 (accessed 19 January 2007)
  3. ^ ISCEV Website
  4. ^ Brigell et al. (2005). "An overview of drug development with special emphasis on the role of visual electrophysiological testing". Doc Ophthalmol. 110 (1): 3–13. PMID 16249953. Retrieved 12 August 2014. 

See also[edit]